Results 1 to 10 of about 1,678,208 (198)
Some of the next articles are maybe not open access.
Structural insight into selectivity of amylin and calcitonin receptor agonists
Nature Chemical Biology, 2023Amylin receptors (AMYRs), heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins, are promising obesity targets. A hallmark of AMYR activation by Amy is the formation of a 'bypass' secondary structural motif (residues S19-P25).
Jianjun Cao +14 more
openaire +2 more sources
Oral delivery of the amylin receptor agonist pramlintide
Peptide Science, 2023Abstract Amylin receptor agonism safely benefit diabetic patients, reducing the insulin requirements and glycemic excursions. Pramlintide is the triple proline human amylin analogue first used as injectable drug, but lacking physico‐chemical compatibility when co‐formulated with insulin. Here, we report the design and characterization
Celimar Sinézia +3 more
openaire +1 more source
Amylin is an agonist of the renal porcine calcitonin receptor.
Endocrinology, 1994The cloned renal porcine calcitonin (pCT) receptor cDNA expressed by transient transfection in COS-1 cells or stable transfection in HEK-293 cells was assayed for interaction with CT, amylin, and CT gene-related peptide. Both [125I]salmon CT ([125I]sCT) and [125I]rat amylin displayed specific binding to transfected cells, and in both cases, pCT and rat
P M, Sexton +4 more
openaire +3 more sources
European Journal of Pharmacology, 2023
Pharmacotherapies for obesity and type 2 diabetes (T2D) are thought to bridge the gap between lifestyle modification and the weight loss obtained with bariatric surgery. Although the effect of monotherapies, namely amylin and glucagon-like peptide-1 receptor (GLP-1R) agonists, has shown great potential, combination therapy is now becoming a strategy to
Simone A. Melander +3 more
openaire +2 more sources
Pharmacotherapies for obesity and type 2 diabetes (T2D) are thought to bridge the gap between lifestyle modification and the weight loss obtained with bariatric surgery. Although the effect of monotherapies, namely amylin and glucagon-like peptide-1 receptor (GLP-1R) agonists, has shown great potential, combination therapy is now becoming a strategy to
Simone A. Melander +3 more
openaire +2 more sources
Structure, Self-Association, and Aggregation Properties of a Long-Acting Amylin Receptor Agonist
Molecular PharmaceuticsPharmacokinetic (PK) properties of therapeutic peptides can be extended through covalent conjugation to albumin-binding fatty acids. The present study examines the effects of fatty acid conjugation and vehicle composition on structure, self-association pattern, and aggregation propensity of an amylin analogue.
Christian Poulsen +3 more
openaire +2 more sources
Dual amylin and calcitonin receptor agonists as multifaceted disease-modifying osteoarthritis drugs
International Journal of ObesityObesity is a powerful driver in the development and progression of osteoarthritis (OA), contributing to increased mechanical load and metabolic stress, making it a valuable target for treatment. Weight loss is a cornerstone of OA management, improving patients' quality of life and disease outcomes.
Khaled Elhady Mohamed +6 more
openaire +4 more sources
894-P: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist
DiabetesIntroduction and Objective: MET-233 is an ultra-long acting (ULA) amylin analog being evaluated in clinical trials for the treatment of obesity. We sought preclinical proof of concept that MET-233, designed to be combined with GLP-1R agonist MET-097, is an effective candidate for obesity treatment. Methods: MET-233 emerged from an amylin
JAMES S. MINNION +2 more
openaire +1 more source
1664-P: Discovery of Selective, Long-Acting Amylin Receptor Agonist for Obesity
DiabetesIntroduction and Objective: CH-AM-1 to 3 are potent, long-acting amylin receptor agonists under research for obesity. Unlike some amylin agonist molecules (e.g. Cagrilintide), they are designed to have minimal calcitonin activity. Methods: Peptides were designed and tested in cAMP assay for activity against AMY1R, AMY3R and ...
SPRING(ZUCHUN) ZHAO +6 more
openaire +1 more source

